← The library
Pinealon
region-specificCognition/MoodEvidence grade
BRegion-specific approval (not US FDA)
Cardiovascular · 0–5 · separate axis
0
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeCognition / Mood
MechanismShort peptide bioregulator from the Khavinson series, studied for neuronal protection
EffectsStudied for neuronal resilience; human evidence is limited and largely single-group
DosingNo human dose established.
Bottom lineApproved in some jurisdictions; not FDA-reviewed, so US access is via unregulated channels.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce daily, morning or early afternoon
Starting1.0 mg SC daily, days 1-5
Escalation1.5 mg days 6-14
Target2.0 mg days 15-20
Cycle10-20 days (some to 28); 2-3 months off
No Western RCT. The only human data are small Russian oral reports, which do not map to SC dosing.
Batches on filenone
No tested batches on file.
Cautions & interactions
Not FDA-approved; approval and quality standards vary by country
Limited interaction data; discuss with a clinician.
CV 0 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.